NCT00834574已完成1 期
A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Cmax (Maximum Observed Concentration)
研究概览
简要总结
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under fasting conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects selected for this study will be non-smokers at least 18 years of age. Subjects will have a BMI (body mass index) between 19 kg/m² and 30 kg/m² (inclusive).
- •Each subject will be given a general physical examination within 28 days of initiation of the study. Such examination includes but is not limited to blood pressure, general observations, and history.
- •Each female subject will be given a serum pregnancy test as part of the pre-study screening process.
- •Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.
- •Clinical laboratory measurements will include the following:
- •Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell count (with differential).
- •Clinical Chemistry: creatinine, BUN, glucose, SGOT, SGPT, bilirubin, and alkaline phosphatase.
- •Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
- •HIV Screen
- •Hepatitis-B, C Screen
- •Drugs of Abuse Screen: pre-study and at each dosing period check-in
- •Subjects will be selected if all above are normal. Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.
排除标准
- •Subjects with a history of alcoholism or drug addiction (during past 2 years) or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects whose clinical laboratory test values are outside the reference range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
- •Subjects who have a history of allergic responses to the class of drug being tested (including penicillin, any penicillin derivative, or any cephalosporin product) should be excluded from the study.
- •All subjects will have urine/saliva samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each study period check-in. Subjects found to have urin/saliva concentrations of any of the tested drugs will not be allowed to participate.
- •Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
- •Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
- •Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Subjects who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study dosing, or used oral hormonal contraceptives within 14 days before dosing will not be allowed to participate.
- •All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.
- •Subjects who do not tolerate venipuncture will not be allowed to participate.
- •Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is require.
- •Subjects who have difficulty fasting or consuming the standard meals will not be allowed to participate.
- •Subjects who have had a clinically significant illness within 4 weeks prior to the first dosing of the study will not be allowed to participate.
- •Subjects who have used a known hepatic enzyme inducer or inhibitor within 30 days prior to the first dosing of the study will not be allowed to participate.
研究组 & 干预措施
1
Experimental
干预措施: Cefdinir for oral suspension 250 mg/5mL (Drug)
2
Active Comparator
干预措施: OMNICEF® for oral suspension 250 mg/5mL (Drug)
结局指标
主要结局
Cmax (Maximum Observed Concentration)
时间窗: Blood samples collected over a 14 hour period.
Bioequivalence based on Cmax.
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
时间窗: Blood samples collected over a 14 hour period.
Bioequivalence based on AUC0-t.
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
时间窗: Blood samples collected over a 14 hour period.
Bioequivalence based on AUC0-inf.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Cefdinir for Oral Suspension 250 mg/5mL, Non-fastingHealthyNCT00835549Teva Pharmaceuticals USA32
已完成
1 期
Cefprozil for Oral Suspension 250 mg/5 mL, FastingHealthyNCT00835614Teva Pharmaceuticals USA26
已完成
1 期
Cefprozil for Oral Suspension 250 mg/5 mL, Non-fastingHealthyNCT00835354Teva Pharmaceuticals USA26
已完成
1 期
Cefdinir Capsules 300 mg, FastingHealthyNCT00835484Teva Pharmaceuticals USA32
已完成
1 期
Cefdinir Capsules 300 mg, Non-fastingHealthyNCT00834535Teva Pharmaceuticals USA32